ArticleJACC. Case reports2025
Right Ventricular Volume Unload: Transcatheter Tricuspid Valve Replacement in Congenital Heart Disease.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe population of adults with repaired congenital heart disease is increasing, and given their frequent history of repeated surgeries, they are the ones that may benefit the most from less-invasive therapeutic options, in order to truly address their disease with a lifespan-management perspective. Tetralogy of Fallot patients frequently present with significant tricuspid regurgitation which has been associated with adverse clinical events. CASE SUMMARY: We report hereinafter on a successful transcatheter tricuspid valve replacement (TTVR) in a middle-age Tetralogy of Fallot patient at high surgical risk. Our aim is to emphasize on the technical challenges but also on the major benefits of the procedure, either from a symptomatic or structural remodeling standpoint. DISCUSSION: TTVR represents a promising therapy for this underserved subgroup of patients. TAKE-HOME MESSAGES: TTVR in Tetralogy of Fallot patients is feasible. Despite the frequent advanced and chronic right ventricular adverse remodeling observed in this population, those patients may derive a great benefit from the procedure. Right ventricular reverse remodeling was associated with major symptomatic and functional improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.